AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11197587
Drug: Zanamivir 10
RxNorm normalized name: Zanamivir 10 mg/mL solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir 10 mg inhaled twice daily
Trial: 11197587
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg orally twice daily
Trial: 11197587
Drug: Zanamivir 10
RxNorm normalized name: Zanamivir 10 mg/mL solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir 10 mg inhaled once daily for prophylaxis
Trial: 11197587
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg orally once daily for prophylaxis
Trial: 9103722
Drug: Daily urge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily urge intensity measures
Trial: 7957037
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium bromide (160 micrograms, dry powder) added to stimulation in one patient with obstructive lung disease
Trial: 3066896
Drug: Amitriptyline or
RxNorm normalized name: amitriptyline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline or Imipramine treatment
Trial: 31549943
Drug: Machine learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine learning (ML)‐based CT fractional flow reserve (FFR)
Trial: 23681144
Drug: Automated alert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated alert recommending lung-protective ventilation with a Vt of 6 cc/kg predicted body weight
Trial: 17573205
Drug: Enhanced cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced cognitive-behavioral therapy (MET+CBT)
Trial: 9495400
Drug: ondansetron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (0.1 mg/kg, n = 26)
Trial: 9495400
Drug: dimenhydrinate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dimenhydrinate (0.5 mg/kg, n = 25)
Trial: 7852614
Drug: 0.1% methylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% methylene blue gel irrigated at 0, 1, and 4 weeks
Trial: 23514036
Drug: Heme Iron
RxNorm normalized name: HEME IRON
DrugBank: Ferroheme (DB18267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heme Iron Polypeptide (HIP) 11 mg orally 3 times per day
Trial: 23514036
Drug: IV iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV iron sucrose 200 mg monthly for 6 months
Trial: 6436182
Drug: Cefroxadine 250
RxNorm normalized name: cefroxadine
DrugBank: Cefroxadine (DB11367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefroxadine 250 mg q.i.d. for ten days
Trial: 6436182
Drug: Cephalexin 500
RxNorm normalized name: cephalexin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 500 mg q.i.d. for ten days
Trial: 31469303
Drug: Lixisenatide combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide combined with basal insulin
Trial: 29271022
Drug: Weekly supplementation
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly supplementation (120 mg elemental iron, 3 mg folic acid, 100 mg vitamin C)
Trial: 29271022
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation (60 mg elemental iron, 1 mg folic acid, 100 mg vitamin C)
Trial: 18827074
Drug: XP13512 immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP13512 immediate-release (up to 2800 mg single dose and 2100 mg twice daily)
Trial: 18827074
Drug: XP13512 extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP13512 extended-release (equimolar dose compared with 600 mg gabapentin)
Trial: 18827074
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin (up to 1200 mg)
Trial: 16114985
Drug: Patient-specific vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-specific vaccine (3 weekly injections of irradiated tumor cells)
Trial: 6139119
Drug: Diazepam 27
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 27 mg
Trial: 30545596
Drug: Swallowable gas-filled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowable gas-filled intragastric balloon system plus lifestyle therapy
Trial: 30545596
Drug: Lifestyle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle therapy alone
Trial: 26821696
Drug: Epinephrine 0.05
RxNorm normalized name: EPINEPHrine 0.05 % Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine 0.05 µg kg(‐1) min(‐1) infusion
Trial: 24613294
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (6 soft-gel capsules of fish oil daily for 4 months)
Trial: 24613294
Drug: Placebo (paraffin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (paraffin oil capsules)
Trial: 22273457
Drug: Intracoronary bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary bolus and continuous intravenous infusion of eptifibatide (Group B, n=88)
Trial: 19798503
Drug: PGB-monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGB-monotherapy
Trial: 19798503
Drug: Non-PGB drugs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PGB drugs
Trial: 15669555
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (HRT) with 2 mg estradiol valerate and 2 mg dienogest
Trial: 12499617
Drug: Nicorandil cocktail
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil cocktail (24 mg nicorandil, 5 mg nitroglycerin, 10,000 U heparin)
Trial: 12499617
Drug: Verapamil cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil cocktail (10 mg verapamil, 5 mg nitroglycerin, 10,000 U heparin)
Trial: 1479795
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tyrosine per kg body weight per day
Trial: 30291682
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of cytidine (2%, 3%, and 4% w/w)
Trial: 30291682
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control formulation
Trial: 29609720
Drug: Saline bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline bolus of 22 mL/kg body weight
Trial: 29609720
Drug: Minimum rate
RxNorm normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minimum rate saline infusion (control)
Trial: 19747047
Drug: ICP-targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-targeted therapy based on the Lund concept
Trial: 15694110
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 microg/24 h (Femseven)
Trial: 12400528
Drug: Tetravalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent meningococcal polysaccharide vaccine conjugated to diphtheria at 1, 4, and 10 microg/ml dosages
Trial: 12400528
Drug: Tetravalent meningococcal
RxNorm normalized name: MENINGOCOCCAL B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent meningococcal polysaccharide vaccine conjugated to diphtheria at 4 microg/ml
Trial: 31488289
Drug: T+S (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+S (0.5 mg testosterone and 50 mg sildenafil) under fed conditions
Trial: 31488289
Drug: T+S (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+S (0.5 mg testosterone and 50 mg sildenafil) under fasted conditions
Trial: 19419443
Drug: Adjunctive intra-muscular
RxNorm normalized name: Orchis mascula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive intra-muscular neridronate (12.5 mg injection/week for 3 months)
Trial: 19419443
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment (PT) only
Trial: 16393441
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (0.2 mg)
Trial: 16393441
Drug: Desloratadine tablets
RxNorm normalized name: Desloratadine Tablets
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine tablets (5 mg)
Trial: 9215017
Drug: Hyaluronidase 300
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase 300 iu ml‐1
Trial: 9215017
Drug: Hyaluronidase 50
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase 50 iu ml‐1
Trial: 7535064
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (high-dose, low-dose, placebo)
Trial: 7535064
Drug: Aprotinin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high and low doses)
Trial: 3555584
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg + HCTZ 12.5 mg (25/12.5)
Trial: 3555584
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg + HCTZ 25 mg (50/25)
Trial: 3555584
Drug: Captopril 100
RxNorm normalized name: captopril 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 100 mg + HCTZ 50 mg (100/50)
Trial: 26480205
Drug: Telephone-administered psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered psychotherapy (T-P)
Trial: 26480205
Drug: Telephone-administered social
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered social rhythm therapy (T-SRT)
Trial: 26480205
Drug: Telephone-administered intensive
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered intensive clinical management (T-ICM)
Trial: 9892124
Drug: Modified flexible
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified flexible suture implant
Trial: 31866929
Drug: eCBT‐I (automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eCBT‐I (automated Internet‐delivered cognitive behavioral therapy for insomnia)
Trial: 31866929
Drug: mPT (minimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mPT (minimal psychoeducation therapy)
Trial: 26638161
Drug: SoluMatrix meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SoluMatrix meloxicam 10 mg (fasting)
Trial: 26638161
Drug: meloxicam 15
RxNorm normalized name: meloxicam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meloxicam 15 mg tablets (fasting)
Trial: 26638161
Drug: SoluMatrix meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SoluMatrix meloxicam 5 mg (fasting)
Trial: 26638161
Drug: SoluMatrix meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SoluMatrix meloxicam 10 mg
Trial: 22803939
Drug: Person‐Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person‐Based Cognitive Therapy (PBCT) plus Treatment as Usual (TAU)
Trial: 20934698
Drug: Double-bundle ACL
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-bundle ACL reconstruction technique (ST/G)
Trial: 17637192
Drug: Fast release
RxNorm normalized name: Delsym Cough Maximum Strength Fast Release Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast release formulation
Trial: 17637192
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release formulation
Trial: 12180532
Drug: AERx pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AERx pulmonary delivery system with ABT-431 (1, 2, 4, and 8 mg doses)
Trial: 12180532
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of ABT-431 (5 mg over 1 hr)
Trial: 10343980
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol (2 mg every 4 hours until delivery)
Trial: 1944468
Drug: Prolonged administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged administration of epipodophyllotoxin (teniposide with or without etoposide) twice weekly or weekly
Trial: 1944468
Drug: Epipodophyllotoxins administered
RxNorm normalized name: Epidophyllotoxin
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epipodophyllotoxins administered twice weekly
Trial: 1944468
Drug: Epipodophyllotoxins administered
RxNorm normalized name: Epidophyllotoxin
DrugBank: Teniposide (DB00444)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epipodophyllotoxins administered weekly
Trial: 1944468
Drug: No epipodophyllotoxins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No epipodophyllotoxins or treated only during remission induction or every two weeks during continuation treatment
Trial: 6750780
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg penicillamine daily
Trial: 6750780
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg penicillamine daily
Trial: 28536868
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg·kg‐1 body mass)
Trial: 9297732
Drug: Vancomycin intravenous
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin intravenous loading dosage
Trial: 3535661
Drug: Piperacillin (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (18 g/day)
Trial: 3535661
Drug: Cefoxitin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (12 g/day)
Trial: 29802852
Drug: Curcumin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1,500 mg orally, twice per day)
Trial: 27487408
Drug: Live educational
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live educational music therapy
Trial: 27487408
Drug: Recorded educational
RxNorm normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recorded educational music therapy
Trial: 25831695
Drug: Combined anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined anesthesia (CA) with thoracic epidural analgesia using ropivacaine 0.3%, fentanyl 4 µg/ml, and epinephrine 2 µg/ml, followed by epidural infusion of ropivacaine 0.2%, fentanyl 2 µg/ml, and epinephrine 2 µg/ml for 5-7 days post-surgery.
Trial: 23425955
Drug: T40/A5 FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T40/A5 FDC therapy (telmisartan 40 mg + amlodipine 5 mg)
Trial: 10638607
Drug: Combined radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radiation therapy (RT) and chemotherapy (50 Gy in 25 fractions over 5 weeks, plus cisplatin 75 mg/m2 i.v. on specific weeks, and continuous infusion fluorouracil (5FU) 1 g/m2 per day for the first 4 days of the same weeks)
Trial: 10638607
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) alone (64 Gy in 32 fractions over 6.4 weeks)
Trial: 10638607
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy plus esophagectomy (three cycles of preoperative cisplatin and 5FU, two cycles after operation for responding patients)
Trial: 10638607
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin and 5FU)
Trial: 1736753
Drug: Clonidine 0.2
RxNorm normalized name: CLONIDINE 0.2MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.2 mg orally at bedtime
Trial: 31371144
Drug: VRRS‐Tablet (experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRRS‐Tablet (experimental linguistic treatment)
Trial: 31371144
Drug: Traditional linguistic
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional linguistic treatment (control)
Trial: 24699894
Drug: Sucroferric oxyhydroxide
RxNorm normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucroferric oxyhydroxide 1 g
Trial: 22967202
Drug: Internet-based self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based self-help problem solving treatment (PST)
Trial: 10834665
Drug: Serum SLPI
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum SLPI in septic surgical patients (132+/‐15 ng/mL)
Trial: 10834665
Drug: Serum SLPI
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum SLPI in healthy adults after lipopolysaccharide administration (50.2+/‐4.0 ng/mL)
Trial: 1635361
Drug: Prostacyclin (Epoprostenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin (Epoprostenol Wellcome or Chinoin) at a dose of 5 mg/kg/min intravenously in 5 infusions
Trial: 10922161
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine mouthwash (used twice daily)
Trial: 29664853
Drug: FX006 (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX006 (32 mg)
Trial: 29664853
Drug: Saline‐solution placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline‐solution placebo
Trial: 27235297
Drug: Provider and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider and patient/caregiver focused intervention including operational guidelines, systematic training, peer review of antibiotic prescribing, health education to patient caregivers, printed educational materials, and educational videos.
Trial: 25496487
Drug: l-carnitine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine (12 g)
Trial: 23583604
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg per day (including a 2 week run in of 100 mg per day) plus active supportive care
Trial: 23583604
Drug: Thalidomide 200
RxNorm normalized name: thalidomide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide 200 mg per day
Trial: 16373466
Drug: Interactive CD-ROM
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive CD-ROM program on safe medication practices
Trial: 12450908
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron supplementation (1 dose of 60 mg Fe/d)
Trial: 12450908
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplementation (2 doses of 60 mg Fe once weekly)
Trial: 10510150
Drug: Placebo antitussive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo antitussive preceded at 1 h by placebo inhibitor
Trial: 10510150
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral DEX preceded at 1 h by placebo inhibitor (DEX30)
Trial: 10510150
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral DEX preceded at 1 h by placebo inhibitor (DEX60)
Trial: 10510150
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral DEX preceded at 1 h by 50 mg oral quinidine sulphate (QDEX30)
Trial: 8834127
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (prednisone 10-15 mg/day) plus supplementary home oxygen therapy (mean 16.4 h/day) for 4 years.
Trial: 8834127
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (prednisone 10-15 mg/day) without home oxygen therapy for 4 years.
Trial: 2036669
Drug: Propranolol and
RxNorm normalized name: propranolol and thiazides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol and Metoprolol (higher doses)
Trial: 7016223
Drug: Alkeran (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkeran (600 mg/m2 x 5 days every 6 weeks)
Trial: 29259196
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without inhaled nitrous oxide)
Trial: 27069173
Drug: Pre-hydration with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-hydration with 15 mEq magnesium sulfate (Mg-hydration group)